4.6 Article

Prognostic Genetic Biomarkers Based on Oncogenic Signaling Pathways for Outcome Prediction in Patients with Oral Cavity Squamous Cell Carcinoma

期刊

CANCERS
卷 13, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/cancers13112709

关键词

oral cavity squamous cell carcinoma; oncogenic signaling pathway; pathway instability; mutational signatures; disease-free survival; overall survival

类别

资金

  1. Ministry of Science and Technology, Taiwan [MOST-108-2314-B-182A-113 -MY3, MOST-109-2628-B-182A-001]
  2. Chang Gung Memorial Hospital, Linko, Taiwan [CMRPG3G1131-33, CMRPG3H087173, CMRPG3D1061-63, CMRPG3D1071-73, CMRPG3G0593, CIRPG1E0012, CMRPVVK0091, CMRPVVL0021, CMRPG3J0501-02]

向作者/读者索取更多资源

By analyzing mutational signatures and oncogenic signaling pathways in whole exome-sequencing data, a specific subgroup of patients with a significantly negative impact on disease-free and overall survival in OCSCC was identified, revealing potential target genes. The study showed that multiple genes drive the development of oral cavity squamous cell carcinoma in multiple pathways and identified candidate genes and pathways that may serve as prognostic genetic biomarkers or therapeutic targets.
Simple Summary A comprehensive analysis based on mutational signatures and oncogenic signaling pathways to identify a specific subgroup of patients that had a significantly negative impact on both disease-free and overall survival in oral cavity squamous cell carcinoma (OCSCC) from whole exome-sequencing data. This analysis has revealed a variety of biologically relevant candidate target genes. Thirty percent of 165 tumors had multiple targetable alterations in multiple pathways. This suggests the complex interplay and crosstalk of oncogenic signaling pathways play an important role on the outcome of patients with OCSCC, and the candidate genes and pathways identified may include prognostic genetic biomarkers or therapeutic targets for OCSCC. Mutational profiling of patients' tumors has suggested that the development of oral cavity squamous cell carcinoma (OCSCC) is driven by multiple genes in multiple pathways. This study aimed to examine the association between genomic alterations and clinical outcomes in patients with advanced stages OCSCC to facilitate prognostic stratification. We re-analyzed our previous whole-exome sequencing data from 165 long-term follow-ups of stages III and IV patients with OCSCC. Their frequent mutations were mapped to 10 oncogenic signaling pathways. Clinicopathological risk factors, relapse, and survival were analyzed to identify the genetic factors associated with advanced OCSCC. Frequent genetic alterations included point mutations in TP53, FAT1, NOTCH1, CASP8, CDKN2A, HRAS, PIK3CA, KMT2B (also known as MLL4), and LINC00273; amplified segments in CCND1, EGFR, CTTN, and FGFR1; and lost segments in CDKN2A, ADAM3A, and CFHR1/CFHR4. Comprehensive analysis of genetic alterations revealed that subgroups based on mutational signatures had a significant negative impact on disease-free survival (p = 0.0005) and overall survival (p = 0.0024). Several important signaling pathways were identified to be frequently genetically altered in our cohort. A specific subgroup of patients with alterations in NOTCH, RTK/RAS/MAPK, and TGF-beta pathways that had a significantly negative impact on disease-free survival (p = 0.0009). Thirty percent of samples had multiple targetable mutations in multiple pathways, indicating opportunities for novel therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据